MedTrace Logo

Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin

NCT00906529 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2019-01-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether aggressive (goal pre-prandial blood glucose \<110 mg/dl) versus conservative (goal pre-prandial blood glucose \<180mg/dl) diabetes treatment of type 2 diabetic patients on the general medical wards has any effect on hospital outcomes.

Conditions

Interventions

DRUG

Levemir (Detemir) and Novolog (Aspart) Insulin

Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Steve Fordan, MD · University of Texas Southwestern Medical Center

  • John Richard, MD · University of Texas Southwestern Medical Center

  • Philip Raskin, MD · University of Texas Southwestern Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-12-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00906529 on ClinicalTrials.gov